fibrosis

(redirected from Idiopathic pulmonary fibrosis)
Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

fi·bro·sis

 (fī-brō′sĭs)
n.
The formation of excessive fibrous tissue, as in a reparative or reactive process.

fi·brot′ic (-brŏt′ĭk) adj.

fibrosis

(faɪˈbrəʊsɪs)
n
(Pathology) the formation of an abnormal amount of fibrous tissue in an organ or part as the result of inflammation, irritation, or healing
fibrotic adj

fi•bro•sis

(faɪˈbroʊ sɪs)

n.
the development in an organ of excess fibrous connective tissue.
[1870–75]
fi•brot′ic (-ˈbrɒt ɪk) adj.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.fibrosis - development of excess fibrous connective tissue in an organ
pneumoconiosis, pneumonoconiosis - chronic respiratory disease caused by inhaling metallic or mineral particles
cystic fibrosis, fibrocystic disease of the pancreas, mucoviscidosis, pancreatic fibrosis, CF - the most common congenital disease; the child's lungs and intestines and pancreas become clogged with thick mucus; caused by defect in a single gene; no cure is known
pathology - any deviation from a healthy or normal condition
myelofibrosis - fibrosis of the bone marrow
Translations

fibrosis

[faɪˈbrəʊsɪs] nfibrosi f

fi·bro·sis

n. fibrosis, formación anormal de tejido fibroso;
diffuse interstitial pulmonary ______ intersticial del pulmón;
proliferative ______ proliferativa;
retroperineal ______ retroperineal.

fibrosis

n fibrosis f; idiopathic pulmonary — fibrosis pulmonar idiopática; nephrogenic systemic — fibrosis sistémica nefrogénica
References in periodicals archive ?
In all patients with idiopathic pulmonary fibrosis and in all patients with pulmonary fibrosis and COPD, inhalation of the nasal spray demonstrated a significant reduction of coughing and a significant improvement in nasal irritation/erythema, inflammation and congestion, with most patients free of irritation by day 22.
Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Research by Treatment (Drug Class (Mitogen-Activated Protein Kinases (MAPK) Inhibitors, Tyrosine Kinase Inhibitors, Autotaxin Inhibitors, Others), Oxygen Therapy, Lung Transplant, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025
Bronchoscopic lung cryobiopsy increases diagnostic confidence in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.
(1,48) Furthermore, acute flare ups and worsening of idiopathic pulmonary fibrosis correlate with exposure to [O.sub.3], N[O.sub.2], and particulate matter.
Mene Pangalos, Executive Vice President, R&D BioPharmaceuticals, said: Idiopathic pulmonary fibrosis has a significant impact on patients lives and new therapies are urgently needed.
Idiopathic pulmonary fibrosis (IPF) is an age-related and progressive interstitial lung disease, with a life expectancy of 3-5 years after diagnosis.[1] Accumulating evidence indicates that genetic factors, both common and rare variants, contribute significantly to the pathogenesis of IPF.[2] Genome-wide association studies have identified several common variants linked to IPF risk, for example, the most widely replicated variant rs35705950 located in the promoter region of the MUC5B gene.[3],[4],[5] Next generation sequencing (NGS) technologies have facilitated the identification of rare genetic variants.
Recommendations for the management of idiopathic pulmonary fibrosis in South Africa: A position statement of the South African Thoracic Society.
Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.
Idiopathic Pulmonary Fibrosis (IPF) is a devastating disease characterized by scarring and thickening of lung tissue, leading to loss of lung function and, ultimately, death.
Idiopathic pulmonary fibrosis is a chronic fibrotic interstitial lung disease that is a huge health burden worldwide [21].
Food and Drug Administration (FDA) has granted Fast Track designation to Prometic Life Sciences' PBI-4050, a clinical candidate in development for idiopathic pulmonary fibrosis (IPF).
Few ILDs are seen in young age e.g., sarcoidosis, pulmonary Langerhan's cell histiocytosis, and autoimmune pulmonary disorders, whereas idiopathic pulmonary fibrosis (IPF) usually presents between 40 to 70 years of age.

Full browser ?